Is the Debate on the Flecainide Action on the RYR2 in CPVT Closed?
作者信息
Benitah Jean-Pierre, Gómez Ana M
机构信息
Signaling and Cardiovascular Pathophysiology, UMR-S 1180, Inserm, Université Paris-Saclay, France.
出版信息
Circ Res. 2021 Feb 5;128(3):332-334. doi: 10.1161/CIRCRESAHA.121.318706. Epub 2021 Feb 4.
Abstract
摘要
相似文献
1
Is the Debate on the Flecainide Action on the RYR2 in CPVT Closed?关于氟卡尼对儿茶酚胺能多形性室性心动过速（CPVT）中兰尼碱受体2（RYR2）作用的争论结束了吗？
Circ Res. 2021 Feb 5;128(3):332-334. doi: 10.1161/CIRCRESAHA.121.318706. Epub 2021 Feb 4.
2
The mechanism of flecainide action in CPVT does not involve a direct effect on RyR2.氟卡尼在 CPVT 中的作用机制不涉及对 RyR2 的直接作用。
Circ Res. 2015 Apr 10;116(8):1324-35. doi: 10.1161/CIRCRESAHA.116.305347. Epub 2015 Feb 3.
3
Insights on the mechanism of flecainide in catecholaminergic polymorphic ventricular tachycardia.探讨氟卡尼在儿茶酚胺多形性室性心动过速中的作用机制。
J Med Life. 2023 Aug;16(8):1294-1296. doi: 10.25122/jml-2023-0191.
4
Inhibition of cardiac Ca2+ release channels (RyR2) determines efficacy of class I antiarrhythmic drugs in catecholaminergic polymorphic ventricular tachycardia.抑制心脏 Ca2+ 释放通道 (RyR2) 可决定 I 类抗心律失常药物在儿茶酚胺多形性室性心动过速中的疗效。
Circ Arrhythm Electrophysiol. 2011 Apr;4(2):128-35. doi: 10.1161/CIRCEP.110.959916. Epub 2011 Jan 26.
5
A large deletion in RYR2 exon 3 is associated with nadolol and flecainide refractory catecholaminergic polymorphic ventricular tachycardia.RYR2基因第3外显子的大片段缺失与纳多洛尔和氟卡尼难治性儿茶酚胺能多形性室性心动过速相关。
Pacing Clin Electrophysiol. 2019 Aug;42(8):1146-1154. doi: 10.1111/pace.13668. Epub 2019 Apr 17.
6
The direct actions of flecainide on the human cardiac ryanodine receptor: keeping open the debate on the mechanism of action of local anesthetics in CPVT.氟卡尼对人心脏兰尼碱受体的直接作用：关于局部麻醉药在儿茶酚胺相关多形性室性心动过速中作用机制的争论仍在继续。
Circ Res. 2015 Apr 10;116(8):1284-6. doi: 10.1161/CIRCRESAHA.115.306298.
7
Flecainide in patient with aggressive catecholaminergic polymorphic ventricular tachycardia due to novel RYR2 mutation.氟卡尼用于因新型兰尼碱受体2（RYR2）突变导致的侵袭性儿茶酚胺能多形性室性心动过速患者。
Minerva Cardioangiol. 2014 Aug;62(4):363-6.
8
Moving in the right direction: elucidating the mechanisms of interaction between flecainide and the cardiac ryanodine receptor.朝着正确的方向前进：阐明氟卡尼与心脏兰尼碱受体相互作用的机制。
Br J Pharmacol. 2022 Jun;179(11):2558-2563. doi: 10.1111/bph.15718. Epub 2021 Dec 2.
9
Successful treatment of catecholaminergic polymorphic ventricular tachycardia with flecainide: a case report and review of the current literature.氟卡尼成功治疗儿茶酚胺多形性室性心动过速 1 例报告并文献复习
Europace. 2011 Jun;13(6):897-901. doi: 10.1093/europace/euq517. Epub 2011 Feb 2.
10
How does flecainide impact RyR2 channel function?氟卡尼如何影响 RyR2 通道功能？
J Gen Physiol. 2022 Sep 5;154(9). doi: 10.1085/jgp.202213089. Epub 2022 Jun 17.
引用本文的文献
1
Flecainide Specifically Targets the Monovalent Countercurrent Through the Cardiac Ryanodine Receptor, While a Dominant Opposing Ca/Ba Current Is Present.氟卡尼特异性作用于通过心肌兰尼碱受体的单价逆流，同时存在占主导地位的相反钙/钡电流。
Int J Mol Sci. 2024 Dec 29;26(1):203. doi: 10.3390/ijms26010203.
2
Store-Operated Ca Entry as a Putative Target of Flecainide for the Treatment of Arrhythmogenic Cardiomyopathy.作为氟卡尼治疗致心律失常性心肌病假定靶点的储存-操作性钙内流
J Clin Med. 2023 Aug 14;12(16):5295. doi: 10.3390/jcm12165295.
3
Molecular, Subcellular, and Arrhythmogenic Mechanisms in Genetic RyR2 Disease.基因 RyR2 病的分子、亚细胞和心律失常机制。
Biomolecules. 2022 Jul 26;12(8):1030. doi: 10.3390/biom12081030.
本文引用的文献
1
RYR2 Channel Inhibition Is the Principal Mechanism of Flecainide Action in CPVT.RYR2 通道抑制是氟卡尼在 CPVT 中作用的主要机制。
Circ Res. 2021 Feb 5;128(3):321-331. doi: 10.1161/CIRCRESAHA.120.316819. Epub 2020 Dec 10.
2
Ankyrin-B Q1283H Variant Linked to Arrhythmias Via Loss of Local Protein Phosphatase 2A Activity Causes Ryanodine Receptor Hyperphosphorylation.ANK2 Q1283H 变异通过丧失局部蛋白磷酸酶 2A 活性与心律失常相关，导致 Ryanodine 受体过度磷酸化。
Circulation. 2018 Dec 4;138(23):2682-2697. doi: 10.1161/CIRCULATIONAHA.118.034541.
3
Modernized Classification of Cardiac Antiarrhythmic Drugs.心脏抗心律失常药物的现代化分类。
Circulation. 2018 Oct 23;138(17):1879-1896. doi: 10.1161/CIRCULATIONAHA.118.035455.
4
Tracking the sarcoplasmic reticulum membrane voltage in muscle with a FRET biosensor.利用荧光共振能量转移生物传感器跟踪肌肉中的肌浆网膜电压。
J Gen Physiol. 2018 Aug 6;150(8):1163-1177. doi: 10.1085/jgp.201812035. Epub 2018 Jun 13.
5
Flecainide ameliorates arrhythmogenicity through NCX flux in Andersen-Tawil syndrome-iPS cell-derived cardiomyocytes.氟卡尼通过调控安德尔森-塔维尔综合征诱导多能干细胞衍生心肌细胞中的钠钙交换体通量来改善致心律失常性。
Biochem Biophys Rep. 2017 Jan 11;9:245-256. doi: 10.1016/j.bbrep.2017.01.002. eCollection 2017 Mar.
6
Plakophilin-2 is required for transcription of genes that control calcium cycling and cardiac rhythm.桥粒芯蛋白-2是控制钙循环和心律的基因转录所必需的。
Nat Commun. 2017 Jul 24;8(1):106. doi: 10.1038/s41467-017-00127-0.
7
Multiple targets for flecainide action: implications for cardiac arrhythmogenesis.氟卡尼的多种作用靶点：对心脏心律失常发生机制的影响。
Br J Pharmacol. 2018 Apr;175(8):1260-1278. doi: 10.1111/bph.13807. Epub 2017 May 12.
8
Use of flecainide in combination antiarrhythmic therapy in patients with arrhythmogenic right ventricular cardiomyopathy.氟卡尼在致心律失常性右室心肌病患者联合抗心律失常治疗中的应用。
Heart Rhythm. 2017 Apr;14(4):564-569. doi: 10.1016/j.hrthm.2016.12.010. Epub 2016 Dec 9.
9
Catecholaminergic polymorphic ventricular tachycardia: a model for genotype-specific therapy.儿茶酚胺能多形性室性心动过速：一种基因型特异性治疗的模型。
Curr Opin Cardiol. 2017 Jan;32(1):78-85. doi: 10.1097/HCO.0000000000000360.
10
Effect of flecainide derivatives on sarcoplasmic reticulum calcium release suggests a lack of direct action on the cardiac ryanodine receptor.氟卡尼衍生物对肌浆网钙释放的影响表明其对心肌兰尼碱受体缺乏直接作用。
Br J Pharmacol. 2016 Aug;173(15):2446-59. doi: 10.1111/bph.13521. Epub 2016 Jun 29.
Zotero 插件